Patents by Inventor Antje Danielczyk

Antje Danielczyk has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Anti-MUC1 antibody-drug conjugate
    Patent number: 11872289
    Abstract: The present invention pertains to novel antibody drug conjugates (ADC) comprising anti-MUC1 antibody. In particular, said ADC showed significant anti-tumor efficacy.
    Type: Grant
    Filed: August 1, 2022
    Date of Patent: January 16, 2024
    Assignee: DAIICHI SANKYO CO., LTD.
    Inventors: Johanna Gellert, Anke Flechner, Doreen Weigelt, Antje Danielczyk, Akiko Nagase
  • ANTI-MUC1 ANTIBODY-DRUG CONJUGATE
    Publication number: 20230372520
    Abstract: The present invention pertains to novel antibody drug conjugates (ADC) comprising anti-MUC1 antibody. In particular, said ADC showed significant anti-tumor efficacy.
    Type: Application
    Filed: July 10, 2023
    Publication date: November 23, 2023
    Applicant: DAIICHI SANKYO CO., LTD.
    Inventors: Johanna GELLERT, Anke FLECHNER, Doreen WEIGELT, Antje DANIELCZYK, Akiko NAGASE
  • HUMANIZED ANTIBODIES AGAINST LEWIS Y
    Publication number: 20230235076
    Abstract: The present invention pertains to humanized anti-Lewis Y antibodies which specifically bind to Lewis Y and do not show any cross-reactivity. Especially, the humanized anti-Lewis Y antibodies do not bind to Lewis b or any other blood group carbohydrate antigen. In particular, the present invention is directed to humanized anti-Lewis Y antibodies which are useful in the treatment of cancer.
    Type: Application
    Filed: June 29, 2021
    Publication date: July 27, 2023
    Inventors: Antje DANIELCZYK, Johanna GELLERT, Anke FLECHNER, Patrik KEHLER
  • ANTI-MUC1 ANTIBODY-DRUG CONJUGATE
    Publication number: 20230139769
    Abstract: The present invention pertains to novel antibody drug conjugates (ADC) comprising anti-MUC1 antibody. In particular, said ADC showed significant anti-tumor efficacy.
    Type: Application
    Filed: August 1, 2022
    Publication date: May 4, 2023
    Applicant: DAIICHI SANKYO CO., LTD.
    Inventors: Johanna GELLERT, Anke FLECHNER, Doreen WEIGELT, Antje DANIELCZYK, Akiko NAGASE
  • ANTI-MUC1 ANTIBODY
    Publication number: 20210221910
    Abstract: The present disclosure pertains to novel antibodies directed against the cancer antigen MUC1. In particular, an antibody with improved antigen binding was obtained by deleting a glycosylation site in the CDR-H2 of a known anti-MUC1 antibody.
    Type: Application
    Filed: May 17, 2019
    Publication date: July 22, 2021
    Applicant: GLYCOTOPE GMBH
    Inventors: Johanna GELLERT, Anke FLECHNER, Doreen WEIGELT, Antje DANIELCZYK
  • ANTI-MUC1 ANTIBODY-DRUG CONJUGATE
    Publication number: 20210187118
    Abstract: The present disclosure relates to antibody drug conjugates directed against the cancer antigen MUC1. In particular, an antibody with improved antigen binding was obtained by deleting a glycosylation site in the CDR-H2 of a known anti-MUC1 antibody. The conjugates consist of exatecan derivatives coupled to the anti MUC1 antibodies.
    Type: Application
    Filed: May 17, 2019
    Publication date: June 24, 2021
    Applicant: DAIICHI SANKYO CO., LTD.
    Inventors: Johanna GELLERT, Anke FLECHNER, Doreen WEIGELT, Antje DANIELCZYK, Akiko NAGASE
  • Fusion Protein Constructs Comprising an Anti-MUC1 Antibody and IL-15
    Publication number: 20210107961
    Abstract: The present invention pertains to fusion protein constructs comprising an antibody against the cancer antigen MUC1 and IL-15. In particular, the fusion protein constructs activate NK cells and T cells at the cancer site.
    Type: Application
    Filed: March 1, 2019
    Publication date: April 15, 2021
    Inventors: Johanna GELLERT, Patrik KEHLER, Anika JÄKEL, Laura DIX, Antje DANIELCZYK, Steffen GOLETZ
  • PD-L1 AND TA-MUC1 ANTIBODIES
    Publication number: 20200148785
    Abstract: The present invention relates to an antibody which effects enhanced T cell activation in comparison to a reference antibody being glycosylated including more than 80% core-fucosylation and wherein T cell activation is effected by an antibody characterized by enhanced binding to Fc#RIIIa. Said antibody is glycosylated, but essentially lacks core-fucosylation.
    Type: Application
    Filed: March 28, 2018
    Publication date: May 14, 2020
    Inventors: Patrik Kehler, Steffen Goletz, Antje Danielczyk, Johanna Ruehmann, Christoph Goletz
  • MULTISPECIFIC ANTIBODY CONSTRUCTS BINDING TO MUC1 AND CD3
    Publication number: 20200131275
    Abstract: The present invention pertains to multispecific antibody constructs directed against the cancer antigen MUC1 and the T cells antigen CD3. In particular, the multispecific antibody constructs recruit T cells to the cancer site. The design of the multispecific antibody constructs show strong antigen binding and high T cell activation.
    Type: Application
    Filed: March 27, 2018
    Publication date: April 30, 2020
    Inventors: Steffen GOLETZ, Patrik KEHLER, Johanna GELLERT, Antje DANIELCZYK, Anika JÄKEL
  • HUMANIZED ANTI-CD40 ANTIBODIES
    Publication number: 20200087410
    Abstract: The present invention pertains to humanized anti-CD40 antibodies having antigen binding properties similar to those of the parent chimeric anti-CD40 antibody and increased Fc? receptor binding affinities. In particular, the present invention is directed to humanized anti-CD40 antibodies which are useful in the treatment of cancer, infections and immunodeficiencies.
    Type: Application
    Filed: March 27, 2018
    Publication date: March 19, 2020
    Applicant: Glycotope GmbH
    Inventors: Steffen GOLETZ, Antje DANIELCZYK, Anja LOFFLER, Doreen WEIGELT, Patrick KEHLER
  • USE OF HUMAN CELLS OF MYELOID LEUKAEMIA ORIGIN FOR EXPRESSION OF ANTIBODIES
    Publication number: 20190359731
    Abstract: The invention relates to a method for producing a protein molecule composition having a defined glycosylation pattern, comprising (a) introducing in a host cell which is an immortalized human blood cell at least one nucleic acid encoding at least a part of said protein; and (b) culturing said host cell under conditions which permit the production of said protein molecule composition; and (c) isolating said protein molecule composition.
    Type: Application
    Filed: April 5, 2019
    Publication date: November 28, 2019
    Inventors: Steffen GOLETZ, Antje DANIELCZYK, Hans BAUMEISTER, Renate STAHN, Anja LOEFFLER, Lars STOECKL
  • Use of human cells of myeloid leukemia origin for expression of antibodies
    Patent number: 10280230
    Abstract: The invention relates to a method for producing a protein molecule composition having a defined glycosylation pattern, comprising (a) introducing in a host cell which is an immortalized human blood cell at least one nucleic acid encoding at least a part of said protein; and (b) culturing said host cell under conditions which permit the production of said protein molecule composition; and (c) isolating said protein molecule composition.
    Type: Grant
    Filed: May 4, 2015
    Date of Patent: May 7, 2019
    Assignee: Glycotope GmbH
    Inventors: Steffen Goletz, Antje Danielczyk, Hans Baumeister, Renate Stahn, Anja Loeffler, Lars Stoeckl
  • Eukaryotic expression vectors comprising regulatory elements of the globin gene clusters
    Patent number: 10184135
    Abstract: The present invention pertains to the field of recombinant protein production. Novel expression cassettes comprising elements of the human globin gene clusters are provided which show enhanced expression rates of proteins or polypeptides of interest.
    Type: Grant
    Filed: March 30, 2016
    Date of Patent: January 22, 2019
    Assignee: Glycotope GmbH
    Inventors: Steffen Goletz, Doreen Jahn, Antje Danielczyk
  • EUKARYOTIC EXPRESSION VECTORS COMPRISING REGULATORY ELEMENTS OF THE GLOBIN GENE CLUSTERS
    Publication number: 20180094279
    Abstract: The present invention pertains to the field of recombinant protein production. Novel expression cassettes comprising elements of the human globin gene clusters are provided which show enhanced expression rates of proteins or polypeptides of interest.
    Type: Application
    Filed: March 30, 2016
    Publication date: April 5, 2018
    Applicant: Glycotope GmbH
    Inventors: Steffen GOLETZ, Doreen JAHN, Antje DANIELCZYK
  • GLYCOOPTIMIZED ANTIBODY DRUG CONJUGATES
    Publication number: 20180028680
    Abstract: The present invention relates to antibody-drug conjugates (ADCs) and a method for improving the safety profile of the same, comprising linking an antibody molecule to a drug in order to obtain said ADC, wherein said antibody molecule is obtainable from a host cell selected to produce an antibody molecule composition having specific glycosylation
    Type: Application
    Filed: February 22, 2016
    Publication date: February 1, 2018
    Inventors: Felix HART, Antje DANIELCZYK, Steffen GOLETZ
  • Recognition molecules for the treatment and detection of tumors
    Patent number: 9845361
    Abstract: The invention relates to recognition molecules directed towards tumors, and it also relates to pharmaceutical compositions comprising said recognition molecules, methods for the production of said recognition molecules, and to the use of said recognition molecules in the diagnosis and therapy of tumor diseases.
    Type: Grant
    Filed: June 26, 2014
    Date of Patent: December 19, 2017
    Assignee: GLYCOTOPE GmbH
    Inventors: Steffen Goletz, Antje Danielczyk, Renate Stahn, Uwe Karsten
  • Fab-glycosylated antibodies
    Patent number: 9359439
    Abstract: The present invention pertains to a method for controlling the circulation half-life of antibodies by adjusting the amount of sialic acid in the carbohydrates attached to the Fab part of the antibodies. Furthermore, the present invention provides antibodies having an increased circulation half-life.
    Type: Grant
    Filed: August 10, 2011
    Date of Patent: June 7, 2016
    Assignee: Glycotope GmbH
    Inventors: Steffen Goletz, Antje Danielczyk, Lars Stoeckl
  • Tumor-specific recognition molecules
    Patent number: 9345794
    Abstract: The invention relates to recognition molecules which are directed towards tumors and can be used in the diagnosis and therapy of tumor diseases.
    Type: Grant
    Filed: December 10, 2013
    Date of Patent: May 24, 2016
    Assignee: Glycotype GmbH
    Inventors: Steffen Goletz, Antje Danielczyk, Uwe Karsten, Peter Ravn, Renate Stahn, Peter Astrup Christensen
  • ANTI-CANCER TREATMENTS WITH ANTI-EGFR ANTIBODIES HAVING A LOW FUCOSYLATION
    Publication number: 20160068609
    Abstract: The present invention pertains to the field of cancer therapy using anti-cancer antibodies. The medical use of anti-EGFR antibodies having improved glycosylation characteristics, in particular a reduced fucosylation, is provided which show anti-cancer efficacy and an improved adverse side effect profile.
    Type: Application
    Filed: April 22, 2014
    Publication date: March 10, 2016
    Inventors: Steffen GOLETZ, Antje DANIELCZYK
  • USE OF HUMAN CELLS OF MYELOID LEUKAEMIA ORIGIN FOR EXPRESSION OF ANTIBODIES
    Publication number: 20150368363
    Abstract: The invention relates to a method for producing a protein molecule composition having a defined glycosylation pattern, comprising (a) introducing in a host cell which is an immortalized human blood cell at least one nucleic acid encoding at least a part of said protein; and (b) culturing said host cell under conditions which permit the production of said protein molecule composition; and (c) isolating said protein molecule composition.
    Type: Application
    Filed: May 4, 2015
    Publication date: December 24, 2015
    Inventors: Steffen GOLETZ, Antje DANIELCZYK, Hans BAUMEISTER, Renate STAHN, Anja LOEFFLER, Lars STOECKL